Increased expression of EphA2 and E-N cadherin switch in primary hepatocellular carcinoma

Tumori

Volumn 99, Issue 6, 2013, Pages 689-696

  Fan, Min ^a,b   Liu, Yu ^a,c   Xia, Fada ^a   Wang, Zhuolu ^a   Huang, Yun ^a   Li, Jingdong ^a   Wang, Zhiming ^a   Li, Xinying ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Yueyang First People's Hospital   (China)

Author keywords

E cadherin; Ephrin type a receptor 2; Epithelial mesenchymal transition; N cadherin; Primary hepatocellular carcinoma copyright Il pensiero scientifico editore

Indexed keywords

ADULT; AGED; ANTIGENS, CD; CADHERINS; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, EPHA2; UP-REGULATION;

EID: 84894260719     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1390.15457     Document Type: Article

References (31)

1. Dai M, Ren JS, Li N, Li Q, Yang L, Chen YH: [estimation and prediction on cancer related incidence and mortality in china, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi, 33: 57-61, 2012.
2. Waly Raphael S, Yangde Z, Yuxiang C: Hepatocellular carcinoma: Focus on different aspects of management. ISRN Oncol, 2012: 421673, 2012.
3. Yuan W, Chen Z, Wu S, Guo J, Ge J, Yang P, Huang J: Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma, 59: 105-113, 2012.
4. Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H: EphA2 is a critical oncogene in melanoma. Oncogene, 30: 4921-4929, 2011.
5. Hou F, Yuan W, Huang J, Qian L, Chen Z, Ge J, Wu S, Chen J, Wang J: Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients. Med Oncol, 29: 2691-2700, 2012.
6. Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H, Yang P, Hu B, Zhang GW, Chen ZH: Over-expression of EphA2 and ephrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci, 54: 2410-2417, 2009.
7. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Maruyama K, Nakamura T, Arai H, Kajimura M, Hanai H, Tanaka M, Sugimura H: Correlation of EphA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci, 95: 136-141, 2004. (Pubitemid 38404314)
8. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, Kawaguchi Y, Fujimoto K, Hosotani R, Imamura M: N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res, 10: 4125-4133, 2004. (Pubitemid 38812492)
9. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate, 41: 275-280, 1999.
10. Yang P, Yuan W, He J, Wang J, Yu L, Jin X, Hu Y, Liao M, Chen Z, Zhang Y: Overexpression of epha2, mmp-9, and mvd-cd34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res, 39: 1169-1177, 2009.
11. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H, Mikulits W: Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol, 5: 1169-1179, 2009.
12. Orsulic S, Kemler R: Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci, 113 (Pt 10): 1793-1802, 2000. (Pubitemid 30333128)
13. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ: Ve-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: Implications for vasculogenic mimicry. Cancer Biol Ther, 5: 228-233, 2006. (Pubitemid 43327544)
14. Gao ZH: Predictive markers for postsurgical recurrence of hepatocellular carcinoma. J Surg Oncol, 92: 274-275, 2005. (Pubitemid 41779282)
15. Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG: EfnA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma. Int J Cancer, 126: 940-949, 2010.
16. Ishikawa M, Miyahara R, Sonobe M, Horiuchi M, Mennju T, Nakayama E, Kobayashi M, Kikuchi R, Kitamura J, Imamura N, Huang CL, Date H: Higher expression of EphA2 and Ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer, 76: 431-438, 2012.
17. Wykosky J, Debinski W: The EphA2 receptor and EphrinA1 ligand in solid tumors: Function and therapeutic targeting. Mol Cancer Res, 6: 1795-1806, 2008.
18. Cho SB, Lee KH, Lee JH, Park SY, Lee WS, Park CH, Kim HS, Choi SK, Rew JS: Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma. Pathol Int, 58: 635-642, 2008.
19. Islam S, Carey TE, Wolf GT, Wheelock MJ, Johnson KR: Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J Cell Biol, 135: 1643-1654, 1996. (Pubitemid 26427658)
20. Asano K, Duntsch CD, Zhou Q, Weimar JD, Bordelon D, Robertson JH, Pourmotabbed T: Correlation of N-cadherin expression in high-grade gliomas with tissue invasion. J Neurooncol, 70: 3-15, 2004. (Pubitemid 39193992)
21. Agathanggelou A, Bieche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S, Gao B, Minna JD, Downward J, Maher ER, Latif F: Identification of novel gene expression targets for the ras association domain family 1 (rassf1a) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res, 63: 5344-5351, 2003. (Pubitemid 37139849)
22. Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, Kudo A, Fukayama M, Grigoriadis AE: Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer, 104: 147-154, 2003. (Pubitemid 36249788)
23. Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono, K Seki S, Fukushima S, Tsao MS, Sugimura T, Ushijima T: Identification of 27 5′ cpg islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene, 23: 8705-8710, 2004. (Pubitemid 39576479)
24. Zhan DQ, Wei S, Liu C, Liang BY, Ji GB, Chen XP, Xiong M, Huang ZY: Reduced N-cadherin expression is associated with metastatic potential and poor surgical outcomes of hepatocellular carcinoma. J Gastroenterol Hepatol, 27: 173-180, 2012.
25. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2: 442-454, 2002.
26. Quattrocchi L, Green AR, Martin S, Durrant L, Deen S: The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch, 459: 21-29, 2011.
27. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H: E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer, 105: 1885-1893, 2011.
28. Jager T, Becker M, Eisenhardt A, Tilki D, Totsch M, Schmid KW, Romics I, Rubben H, Ergun S, Szarvas T: The prognostic value of cadherin switch in bladder cancer. Oncol Rep, 23: 1125-1132, 2010.
29. Hao L, Ha JR, Kuzel P, Garcia E, Persad S: Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through twist and snail. Br J Dermatol, 166: 1184-1197, 2012.
30. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ: N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol, 147: 631-644, 1999.
31. Kuphal S, Bosserhoff AK: Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene, 25: 248-259, 2006. (Pubitemid 43083686)